Answer
More than 1,000 prospective pregnancy outcomes following first-trimester exposure to raltegravir 400 mg twice daily indicate no malformative toxicity.
Sources for this answer
- Isentress 400 mg Film-coated TabletsMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 37Document updated
Sources checked